Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals
Andrew E. Simor,Tammy L. Stuart,Lisa Louie,Christine Watt,Marianne Ofner-Agostini,Denise Gravel,Michael R. Mulvey,Mark Loeb,Allison McGeer,Allison McGeer,Elizabeth Bryce,Anne Matlow +11 more
TL;DR: The results indicate that the incidence of HLMupr is increasing among Canadian strains of MRSA and that HLM upr MRSA is recovered from patients with distinct clinical and epidemiologic characteristics compared to the characteristics of patents with Mups MRSA strains.
Journal ArticleDOI
Detection and prevalence of inducible clindamycin resistance in staphylococci.
TL;DR: A simple, reliable method for detecting inducible resistance to CL in erythromycin-resistance (ER-R) isolates of S. aureus and CNS is demonstrated and clinical microbiology laboratories should use the double-disc diffusion test as standard practice with all ER-R staphylococci.
Journal ArticleDOI
Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.
TL;DR: In young children (<2 years) with AOM, this study suggests that PCV13 has an impact on overall PNP carriage, as well as on serotypes 19A, 7F, and 6C.
Neisseria gonorrhoeae Treatment Failure andSusceptibilitytoCefiximeinToronto,Canada
Vanessa Allen,Christine Seah,Irene Martin,Colin Lee,Heather Siebert,Roberto G. Melano,Donald E. Low +6 more
TL;DR: Cefixime is the only oral cephalosporin recommended for gonorrhea treatment, critical to the success of expedited partner therapy as mentioned in this paper, but it is not recommended as a front-line therapy.
Journal ArticleDOI
Production of a New Thiopeptide Antibiotic, TP-1161, by a Marine Nocardiopsis Species
Kerstin Engelhardt,Kristin F. Degnes,Michael Kemmler,Harald Bredholt,Espen Fjærvik,Geir Klinkenberg,Håvard Sletta,Trond E. Ellingsen,Sergey B. Zotchev +8 more
TL;DR: The in vitro antibacterial activity of this thiopeptide, designated TP-1161, against a panel of bacterial strains was determined and structure elucidation revealed this compound to be a new thiOPEptide antibiotic with a rare aminoacetone moiety.